[go: up one dir, main page]

MX2022016197A - Anticuerpos anti-cd46 condicionalmente activos, fragmentos de anticuerpo, sus inmunoconjugados y sus usos. - Google Patents

Anticuerpos anti-cd46 condicionalmente activos, fragmentos de anticuerpo, sus inmunoconjugados y sus usos.

Info

Publication number
MX2022016197A
MX2022016197A MX2022016197A MX2022016197A MX2022016197A MX 2022016197 A MX2022016197 A MX 2022016197A MX 2022016197 A MX2022016197 A MX 2022016197A MX 2022016197 A MX2022016197 A MX 2022016197A MX 2022016197 A MX2022016197 A MX 2022016197A
Authority
MX
Mexico
Prior art keywords
antibodies
antibody fragments
immunoconjugates
chain variable
variable region
Prior art date
Application number
MX2022016197A
Other languages
English (en)
Inventor
Gerhard Frey
Hwai Wen Chang
Jay M Short
Jing Wang
Chao Xing
Original Assignee
Bioatla Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioatla Inc filed Critical Bioatla Inc
Publication of MX2022016197A publication Critical patent/MX2022016197A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Optics & Photonics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Food Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Polipéptidos aislados que tienen una región variable de cadena pesada y/o región variable de cadena ligera que se une específicamente a la proteína CD46 así como anticuerpos y fragmentos de anticuerpo que contienen la región variable de cadena pesada y/o la región variable de cadena ligera que se une a la proteína CD46; también se proporcionan inmunoconjugados, composiciones farmacéuticas y kits que comprenden el polipéptido y anticuerpos y fragmentos de anticuerpo que contienen el polipéptido.
MX2022016197A 2020-06-18 2021-06-15 Anticuerpos anti-cd46 condicionalmente activos, fragmentos de anticuerpo, sus inmunoconjugados y sus usos. MX2022016197A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063040913P 2020-06-18 2020-06-18
PCT/US2021/037400 WO2021257542A1 (en) 2020-06-18 2021-06-15 Conditionally active anti-cd46 antibodies, antibody fragments, their immunoconjugates and uses thereof

Publications (1)

Publication Number Publication Date
MX2022016197A true MX2022016197A (es) 2023-04-05

Family

ID=79268294

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022016197A MX2022016197A (es) 2020-06-18 2021-06-15 Anticuerpos anti-cd46 condicionalmente activos, fragmentos de anticuerpo, sus inmunoconjugados y sus usos.

Country Status (11)

Country Link
US (1) US20230242662A1 (es)
EP (1) EP4168452A4 (es)
JP (1) JP2023531189A (es)
KR (1) KR20230023800A (es)
CN (1) CN115702167A (es)
AU (1) AU2021292486A1 (es)
CA (1) CA3182384A1 (es)
IL (1) IL298902A (es)
MX (1) MX2022016197A (es)
TW (1) TW202214696A (es)
WO (1) WO2021257542A1 (es)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20140014064A (ko) * 2010-09-03 2014-02-05 스템 센트알엑스 인코포레이티드 신규한 조절 인자 및 사용 방법
EP3191524A4 (en) * 2014-09-12 2018-05-30 The Regents of The University of California Macropinocytosing human anti-cd46 antibodies and targeted cancer therapeutics
ES3005158T3 (en) * 2016-11-11 2025-03-14 Univ California Anti-cd46 antibodies and methods of use
CN109535260B (zh) * 2018-11-22 2021-08-10 东南大学 一种靶向cd46的人源嵌合抗原受体及其应用

Also Published As

Publication number Publication date
WO2021257542A1 (en) 2021-12-23
EP4168452A1 (en) 2023-04-26
CA3182384A1 (en) 2021-12-23
US20230242662A1 (en) 2023-08-03
AU2021292486A1 (en) 2023-02-09
KR20230023800A (ko) 2023-02-17
TW202214696A (zh) 2022-04-16
IL298902A (en) 2023-02-01
EP4168452A4 (en) 2024-07-10
JP2023531189A (ja) 2023-07-21
CN115702167A (zh) 2023-02-14

Similar Documents

Publication Publication Date Title
MX2022016192A (es) Anticuerpos anti-nectina-4 condicionalmente activos.
MX2021005048A (es) Anticuerpos anti-ctla4, fragmentos de anticuerpos, sus inmunoconjugados y usos.
MX2022006461A (es) Anticuerpos anti-axl, fragmentos de anticuerpos y sus inmunoconjugados y usos de los mismos.
MX2022009915A (es) Anticuerpos anti-ror2, fragmentos de anticuerpos, sus inmunoconjugados y usos de los mismos.
EA202092825A1 (ru) Анти-sirpa антитела и способы их применения
AU2018256487A1 (en) Antibodies that bind to TL1A and their uses
EA202190542A1 (ru) Сконструированные биспецифические белки
HRP20090517T1 (hr) Protutijela na interleukin-10
EA201491599A1 (ru) Антитела к матриксной металлопротеиназе 9
MX377605B (es) Inmunoglobulina híbrida conteniendo un enlace no-peptidílico.
EA201390146A1 (ru) Антитела к матриксной металлопротеиназе 9
WO2020006374A3 (en) Anti-sirp-beta1 antibodies and methods of use thereof
PE20120549A1 (es) Proteinas biespecificas de union a antigenos
EA201490053A1 (ru) Антитела, которые связываются с ox40, и их применение
WO2019195623A3 (en) Heterodimeric antibodies that bind fibroblast activation protein
TN2010000197A1 (en) New antibodies specific of the beta -amyloid peptides and their uses as diagnostic agents or drugs
EA201991912A1 (ru) Составы, содержащие pd-1-связывающие белки, и способы их получения
EA202091054A1 (ru) Слитые молекулы на основе антитела против pd-l1 и ил-7
MX2022007961A (es) Nuevos anticuerpos anti-fgfr2b.
SG10201801219VA (en) Anti-HER2 Antibodies
DE602006007967D1 (de) Gegen das gemeinsame epitop von mutierten p53 gerichtete humane synthetische einzelkettenantikörper und anwendungen davon
PE20201171A1 (es) Anticuerpos de cadena pesada que se unen a cd22
PH12022551398A1 (en) Anti-mertk antibodies and methods of use thereof
EA202092420A1 (ru) Антитело против pd-l1 и его применение
EA201790816A1 (ru) Антитела, которые связываются с ccr6, и варианты применения указанных антител